JAK2 mutations lead to health conditions ... have been approved for the treatment of different forms of IBD, including Rinvoq (upadacitinib) for the treatment of Crohn's disease.

All researchers found the same point mutation in the gene for JAK2 in 65–97 percent of cases of polycythemia vera. The mutation was also present in individuals with the two other ...

“As a first-in-class therapy with a unique mechanism of action as a Type II inhibitor of JAK2, AJ1-11095 was developed to provide a much-needed new treatment for patients with myeloproliferative ...